SIMILAR EFFICACY AND SAFETY OF BIOSIMILAR CANDIDATE BI 695501 AND ADALIMUMAB ORIGINATOR REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS: 24 WEEK RESULTS FROM A PHASE III CLINICAL STUDY (VOLTAIRE®-RA)

被引：2
|
作者：
Cohen, S. [1 ]
Alonso-Ruiz, A. [2 ]
Klimiuk, P. A. [3 ,4 ]
Lee, E. [5 ]
Peter, N. [6 ]
Sonderegger, I. [6 ]
Assudani, D. [6 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] Hosp Cruces, Baracaldo, Spain
[3] Med Univ Bialystok, Bialystok, Poland
[4] Gabinet InternistycznoReumatol, Bialystok, Poland
[5] Inland Rheumatol, Upland, CA USA
[6] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.3405
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0189
引用
收藏
页码：553 / 553
页数：1
相关论文
共 50 条
  • [31] Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis: Results from a Randomized, Double-Blind, Phase III Study
    Xu Huji
    Li Zhijun
    Jian, Wu
    Qian, Xing
    Shi, Guixiu
    Juan, Li
    Xu, Liu
    Wu, Lijun
    Li Xiaomei
    Tan Wenfeng
    He, Dongyi
    Bi Liqi
    Li Hongbin
    Xiao Zhengyu
    Shuai Zongwen
    Li Xiaoxia
    Wang Yongfu
    Li, Luo
    Yi, Zheng
    Xiao Weiguo
    Hui, Zhou
    Lu Yushan
    Zheng Shirui
    Xiong, Wang
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [32] IMPACT OF ADALIMUMAB SERUM CONCENTRATION ON EFFICACY AND ASSOCIATION BETWEEN ANTI-DRUG ANTIBODIES AND SERUM CONCENTRATION: 24 WEEK RESULTS FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Kay, J.
    Weinblatt, M.
    Keystone, E.
    Genovese, M.
    Ghil, J.
    Cheong, S. Y.
    Hong, E. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 136 - 136
  • [33] Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study
    Wiland, Piotr
    Jeka, Slawomir
    Dokoupilova, Eva
    Brandt-Juergens, Jan
    Miranda Limon, Juan Manuel
    Cantalejo Moreira, Miguel
    Veiga Cabello, Raul
    Jauch-Lembach, Julia
    Thakur, Anjali
    Haliduola, Halimuniyazi
    Brueckmann, Ines
    Gaylis, Norman B.
    BIODRUGS, 2020, 34 (06) : 809 - 823
  • [34] Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study
    Piotr Wiland
    Sławomir Jeka
    Eva Dokoupilová
    Jan Brandt-Jürgens
    Juan Manuel Miranda Limón
    Miguel Cantalejo Moreira
    Raul Veiga Cabello
    Julia Jauch-Lembach
    Anjali Thakur
    Halimuniyazi Haliduola
    Ines Brueckmann
    Norman B. Gaylis
    BioDrugs, 2020, 34 : 809 - 823
  • [35] A PHASE III RANDOMISED, DOUBLE-BLIND CLINICAL STUDY COMPARING SB4, AN ETANERCEPT BIOSIMILAR, WITH ETANERCEPT REFERENCE PRODUCT (ENBREL®) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY (24-WEEK RESULTS)
    Vencovsky, J.
    Sylwestrzak, A.
    Leszczynski, P.
    Porawska, W.
    Baranauskaite, A.
    Tseluyko, V.
    Zhdan, V.
    Stasiuk, B.
    Milasiene, R.
    Rodriguez, A. A. Barrera
    Cheong, S. Y.
    Ghil, J.
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 467 - 468
  • [36] SUSTAINED EFFICACY AND COMPARABLE SAFETY AND IMMUNOGENICITY AFTER TRANSITION TO SB5 (AN ADALIMUMAB BIOSIMILAR) VS CONTINUATION OF THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULT OF PHASE III STUDY
    Weinblatt, M.
    Baranauskaite, A.
    Niebrzydowski, J.
    Dokoupilova, E.
    Zielinska, A.
    Sitek-Ziolkowska, K.
    Jaworski, J.
    Racewicz, A.
    Pileckyte, M.
    Jedrychowicz-Rosiak, K.
    Zhdan, V.
    Cheong, S. Y.
    Ghil, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 487 - 487
  • [37] Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study
    Kavanaugh, Arthur
    Allanore, Yannick
    Kucharz, Eugeniusz J.
    Babic, Goran
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [38] A Randomized, Double-Blind Phase III Study Comparing the Efficacy, Safety and Immunogenicity of PF-06438179/GP1111 (Ixifi™), an Infliximab Biosimilar, and Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Active RA: Results from Week 54 to Week 78
    Cohen, Stanley
    Kivitz, Alan J.
    Tee, Michael
    Cronenberger, Carol
    Zhang, Min
    Hackley, Sarah
    Schumacher, Karl
    Rehman, Muhammad I.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [39] Efficacy and Safety Similarity of Biosimilar Adalimumab-aqvh to Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Phase III Study
    Finck, Barbara
    Tang, Helen
    Jensen, Kathy
    Civoli, Francesca
    Tatarewicz, Suzanna
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3620 - 3621
  • [40] EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: SUMMARY RESULTS FROM THE 24-WEEK PHASE III RA-BEACON STUDY
    Zamani, Omid
    Combe, Bernard
    Tony, Hans-Peter
    Sanchez Burson, Juan
    Tahir, Hasan
    Ostergaard, Mikkel
    Augendre-Ferrante, Beatrice
    Beselin, Anke
    Larsson, Esbjorn
    Casillas, Marta
    Smolen, Josef
    RHEUMATOLOGY, 2016, 55 : 93 - 93
12345